Protocol for the examination of specimens from patients with invasive carcinoma of the breast

Archives of Pathology and Laboratory Medicine

Volumn 133, Issue 10, 2009, Pages 1515-1538

  Lester, Susan C ^a   Bose, Shikha ^e   Chen, Yunn Yi ^f   Connolly, James L ^b   De Baca, Monica E ^g   Fitzgibbons, Patrick L ^h   Hayes, Daniel F ⁱ   Kleer, Celina ⁱ   O'Malley, Frances P ^j   Page, David L ^k   Smith, Barbara L ^c   Tan, Lee K ^l   Weaver, Donald L ^m   Winer, Eric ^d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e CEDARS SINAI MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g Physicians Laboratory Ltd   (United States)

^h ST JUDE MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^j MOUNT SINAI HOSPITAL   (Canada)

^k VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^l MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^m UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EOSIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HEMATOXYLIN; PEROXIDASE; PROGESTERONE RECEPTOR;

ACINAR CELL CARCINOMA; ADENOCARCINOMA; ADIPOSE TISSUE; AXILLARY LYMPH NODE; BREAST BIOPSY; BREAST CARCINOMA; BREAST EXAMINATION; BREAST NECROSIS; CALCIFICATION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INVASION; CANCER LOCALIZATION; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CELL ISOLATION; CLINICAL PROTOCOL; DISEASE CLASSIFICATION; EPIDERMIS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENETIC ANALYSIS; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; INVASIVE CARCINOMA; LYMPH NODE; LYMPH NODE METASTASIS; MASTECTOMY; MICROMETASTASIS; MITOSIS RATE; MUSCLE METASTASIS; NIPPLE; PAGET NIPPLE DISEASE; PARTIAL MASTECTOMY; PATHOLOGY; PRACTICE GUIDELINE; QUALITY CONTROL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SEGMENTAL MASTECTOMY; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE BIOPSY; SKELETAL MUSCLE; SKIN METASTASIS; SKIN NODULE; SKIN ULCER; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR CELL; TUMOR DIFFERENTIATION; WORLD HEALTH ORGANIZATION;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CLINICAL PROTOCOLS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; LYMPHATIC METASTASIS; PATHOLOGY, SURGICAL; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 70349646887     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Edge SB, Byrd DR, Carducci MA, Compton CC, eds. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2009.
2. Recommendations of the Association of Directors of Anatomic and Surgical Pathology - Part 1: Immediate management of mammographically detected breast lesions. Hum Pathol. 1993;24(7):689-690. (Pubitemid 23204643)
3. Connolly JL, Schnitt SJ. Evaluation of breast biopsy specimens in patients considered for treatment by conservative surgery and radiation therapy for early breast cancer. Pathol Annu. 1988;23(pt 1):1-23.
4. Schnitt SJ, Wang HH. Histologic sampling of grossly benign breast biopsies: how much is enough? Am J Surg Pathol. 1989;13(6):505-512.
5. Schnitt SJ, Connolly JL. Processing and evaluation of breast excision specimens: a clinically oriented approach. Am J Clin Pathol. 1992;98(1):125-137.
6. Lester SC. Manual of Surgical Pathology. 2nd ed. New York, NY: Elsevier; 2006.
7. Viale G, Dell'Orto P, Biasi MO, et al. Comparative evaluation of an extensive histopathologic examination and a real-time reverse-transcription- polymerase chain reaction assay for mammaglobin and cytokeratin 19 on axillary sentinel lymph nodes of breast carcinoma patients. Ann Surg. 2008;247(1):136-142.
8. Julian TB, Blumencranz P, Deck K, et al. Novel intraoperative molecular test for sentinel lymph node metastases in patients with early-stage breast cancer. J Clin Oncol. 2008;26(20):3338-3345.
9. Singletary SE, Greene FL, Sobin LH. Classification of isolated tumor cells: clarification of the 6th edition of the American Joint Committee on Cancer Staging Manual. Cancer. 2003;98(12):2740-2741. (Pubitemid 37509544)
10. Andea AA, Wallis T, Newman LA, Bouwman D, Dey J, Visscher DW. Pathologic analysis of tumor size and lymph node status in multifocal/multicentric breast carcinoma. Cancer. 2002;94(5):1383-1390. (Pubitemid 34212630)
11. Morrow M, Harris JR. Local management of invasive breast cancer. In: Harris JR, Lippman ME, Morrow M, Osborne KE, eds. Diseases of the Breast. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2000: 522-523.
12. Lester SC, Bose S, Chen Y-Y, et al. Protocol for the examination of specimens from patients with ductal carcinoma in situ of the breast. Arch Pathol Lab Med. 2009;133(1):15-25.
13. Schwartz GF, Lagios MD, Carter D, et al. Consensus conference on the classification of ductal carcinoma in situ. Cancer. 1997;80(9):1798-1802.
14. Tavassoli FA, Devilee P, eds. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon, France: IARC Press; 2003. World Health Organization Classification of Tumours.
15. Ellis IO, Elston CW. Histologic grade. In: O'Malley FP, Pinder SE, eds. Breast Pathology. Philadelphia, PA: Elsevier; 2006: 225-233.
16. Pathology reporting of breast disease: a joint document incorporating the third edition of the NHS Breast Screening Programme's Guidelines for Pathology Reporting in Breast Cancer Screening and the second edition of The Royal College of Pathologists' Minimum Dataset for Breast Cancer Histopathology. NHS Cancer Screening Programmes and The Royal College of Pathologists. January 2005. NHSBSP publication no. 58. http://www.cancerscreening.nhs.uk/breastscreen/ publications/nhsbsp58.html. Accessed April 8, 2009.
17. Torresan RZ, dos Santos CC, Okamura H, Alvarenga M. Evaluation of residual glandular tissue after skin-sparing mastectomies. Ann Surg Oncol. 2005;12(12):1037-1044.
18. Sahoo S, Lester SC. Pathology of breast carcinomas after neoadjuvant chemotherapy: an overview with recommendations on specimen processing and reporting. Arch Pathol Lab Med. 2009;133(4):633-642.
19. Kuroi K, Toi M, Tsuda H, Kurosumi M, Akiyama F. Issues in the assessment of the pathologic effect of primary systemic therapy for breast cancer. Breast Cancer. 2006;13(1):38-48.
20. Pinder SE, Provenzano E, Earl H, Ellis IO. Laboratory handling and histology reporting of breast specimens from patients who have received neoadjuvant chemotherapy. Histopathology. 2007;50(4):409-417. (Pubitemid 46328171)
21. Gonzalez MA, Pinder SE. Invasive carcinoma: other histologic prognostic factors - size, vascular invasion and prognostic index. In: O'Malley FP, Pinder SE, eds. Breast Pathology. Philadelphia, PA: Elsevier; 2006: 235-240.
22. Lee A, DeLellis R, Silverman M, Heatley GJ, Wolfe H. Prognostic significance of peritumoral lymphatic and blood-vessel invasion in node-negative carcinoma of the breast. J Clin Oncol. 1990;8(9):1457-1465. (Pubitemid 20301176)
23. Pinder S, Ellis IO, O'Rourke S, et al. Pathological prognostic factors in breast cancer - vascular invasion: relationship with recurrence and survival in a large series with long-term followup. Histopathology. 1994;24(1):41-47. (Pubitemid 24223138)
24. Rosen PP. Tumor emboli in intramammary lymphatics in breast carcinoma: pathologic criteria for diagnosis and clinical significance. Pathol Annu. 1983;18(pt 2):215-232.
25. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25(33):1-26.
26. National Comprehensive Cancer Network (NCCN) Practice Guideline in Oncology. v.1. 2009. www.nccn.org/professionals/physician-gls/PDF/breast.pdf. Accessed April 8, 2009.
27. Commission on Laboratory Accreditation. Laboratory accreditation program: anatomic pathology checklist. Northfield, IL: College of American Pathologists; Sept 2007. ANP.22988. http://www.cap.org/apps/cap.portal?nfpb= true&pageLabel=eLABLAPpage. Accessed April 8, 2009.
28. Yaziji H, Taylor CR, Goldstein NS, et al. Consensus recommendations on estrogen receptor testing in breast cancer by immunohistochemistry. Appl Immunohistochem Mol Morphol. 2008;16(6):513-520.
29. Gown AM. Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol. 2008;21(suppl 2):S8-S15.
30. Goldstein NS, Ferkowicz M, Odish E, Mani A, Hastah F. Minimum fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma. Am J Clin Pathol. 2003;120:86-92. (Pubitemid 37046374)
31. Arber JM, Arber DA, Jenkins KA, Battifora H. Effect of decalcification and fixation in paraffin-section immunohistochemistry. Appl Immunohistochem. 1996;4(4):241-248. (Pubitemid 27006655)
32. Allred DC. Problems and solutions in the evaluation of hormone receptors in breast cancer. J Clin Oncol. 2008;26(15):2433-2435.
33. Arber DA. Effect of prolonged formalin fixation on the immunohistochemical reactivity of breast markers. Appl Immunohistochem Mol Morphol. 2002;10(2):183-186.
34. Oyama T, Ishikawa Y, Hayashi M, et al. The effects of fixation, processing and evaluation criteria on immunohistochemical detection of hormone receptors in breast cancer. Breast Cancer. 2007;14(2):182-188.
35. Viale G, Regan MM, Maiorano E, et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol. 2007;25(25):3846- 3852. (Pubitemid 47477259)
36. Harvey JM, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17(5):1474-1481.
37. McCarty KS Jr, Miller LS, Cox EB, et al. Estrogen receptor analyses: correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985;109(8):716-721.
38. Shousha S. Oestrogen receptor status of breast carcinoma: Allred/H score conversion table. Histopathology. 2008;53(3):346-347.
39. Collins LC, Botero ML, Schnitt SJ. Bimodal frequency distribution of estrogen receptor immunohistochemical staining results in breast cancer: an analysis of 825 cases. Am J Clin Pathol. 2005;123(1):16-20.
40. Nadji M, Gomez-Fernandez C, Ganjei-Azar P, Morales AR. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am J Clin Pathol. 2005;123(1):21-27. (Pubitemid 40066168)
41. Turbin DA, Leung S, Cheang MCU, et al. Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 cases. Breast Cancer Res Treat. 2008;110(3):417-426. (Pubitemid 351962583)
42. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;25(1):118-145.
43. Vance GH, Barry TS, Bloom KJ, et al. Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. Arch Pathol Lab Med. 2009;133(4):611-612.
44. Selvarajan S, Bay B-H, Choo A, et al. Effect of fixation period on HER2/neu gene amplification detected by fluorescence in situ hybridization in invasive breast carcinoma. J Histochem Cytochem. 2002;50(12):1693-1696. (Pubitemid 36078136)
45. Willmore-Payne C, Metzger K, Layfield LJ. Effects of fixative and fixation protocols on assessment of Her-2/neu oncogene amplification status by fluorescence in situ hybridization. Appl Immunohistochem Mol Morphol. 2007;15(1):84-87. (Pubitemid 46673322)
46. Brown RS, Edwards J, Bartlett JW, Jones C, Dogan A. Routine acid decalcification of bone marrow samples can preserve DNA for FISH and CGH studies in metastatic prostate cancer. J Histochem Cytochem. 2002;50(1):113-115. (Pubitemid 34074629)
47. Ross JS, Hatzis C, Symmans WF, Pusztai L, Hortobagyi GN. Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist. 2008;13(5):477-493. (Pubitemid 351872866)